Synapse

← Cancer Drug Resistance

Papers in Cancer Drug Resistance

Page 4 · newest first

  1. Targeting BCL2 pathways in CLL: a story of resistance and ingenuityCancer Drug Resistance · 2023
  2. Supramolecular host-guest nanosystems for overcoming cancer drug resistanceCancer Drug Resistance · 2023
  3. Emerging roles of 3D-culture systems in tackling tumor drug resistanceCancer Drug Resistance · 2023
  4. Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategiesCancer Drug Resistance · 2023
  5. Unlocking antitumor immunity with adenosine receptor blockersCancer Drug Resistance · 2023
  6. Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivityCancer Drug Resistance · 2023
  7. Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistanceCancer Drug Resistance · 2023
  8. Drug resistance in glioblastoma: from chemo- to immunotherapyCancer Drug Resistance · 2023
  9. Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemiaCancer Drug Resistance · 2023
  10. A review of strategies to overcome immune resistance in the treatment of advanced prostate cancerCancer Drug Resistance · 2023
  11. Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomenaCancer Drug Resistance · 2023
  12. Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatmentCancer Drug Resistance · 2023
  13. Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7Cancer Drug Resistance · 2023
  14. Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemiaCancer Drug Resistance · 2023
  15. A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancerCancer Drug Resistance · 2023
  16. Primary and acquired resistance to first-line therapy for clear cell renal cell carcinomaCancer Drug Resistance · 2023
  17. The multifaceted role of extracellular vesicles in prostate cancer-a reviewCancer Drug Resistance · 2023
  18. The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunitiesCancer Drug Resistance · 2023
  19. Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapyCancer Drug Resistance · 2023
  20. New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancersCancer Drug Resistance · 2023
  21. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effectsCancer Drug Resistance · 2023
  22. Heterotypic signaling of cancer-associated fibroblasts in shaping the cancer cell drug resistanceCancer Drug Resistance · 2023
  23. Targeting regulated cell death pathways in acute myeloid leukemiaCancer Drug Resistance · 2023
  24. Immune checkpoint inhibitors in ovarian cancer: where do we go from here?Cancer Drug Resistance · 2023
  25. Anti-BCMA novel therapies for multiple myelomaCancer Drug Resistance · 2023
  26. miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic LeukemiaCancer Drug Resistance · 2023
  27. How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?Cancer Drug Resistance · 2023
  28. Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistanceCancer Drug Resistance · 2023
  29. Targeting MYC-driven lymphoma: lessons learned and future directionsCancer Drug Resistance · 2023
  30. The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancerCancer Drug Resistance · 2023
  31. New mechanisms of multidrug resistance: an introduction to the Cancer Drug Resistance special collectionCancer Drug Resistance · 2023
  32. Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironmentCancer Drug Resistance · 2023
  33. Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinomaCancer Drug Resistance · 2023
  34. Mitochondria in colorectal cancer stem cells - a target in drug resistanceCancer Drug Resistance · 2023
  35. Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery systemCancer Drug Resistance · 2023
  36. Importance of ROS1 fene fusions in non-small cell lung cancerCancer Drug Resistance · 2023
  37. The multidrug resistance transporter P-glycoprotein confers resistance to ferroptosis inducersCancer Drug Resistance · 2023
  38. Nano-TRAIL: a promising path to cancer therapyCancer Drug Resistance · 2023
  39. The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugatesCancer Drug Resistance · 2023
  40. Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitorsCancer Drug Resistance · 2023
  41. Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinomaCancer Drug Resistance · 2023
  42. Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancerCancer Drug Resistance · 2023
  43. Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cellsCancer Drug Resistance · 2023
  44. Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinomaCancer Drug Resistance · 2023
  45. Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activitiesCancer Drug Resistance · 2023
  46. Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistanceCancer Drug Resistance · 2022
  47. The complex relationship between multiple drug resistance and the tumor pH gradient: a reviewCancer Drug Resistance · 2022
  48. Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survivalCancer Drug Resistance · 2022
  49. Aberrant Notch signaling in gliomas: a potential landscape of actionable converging targets for combination approach in therapies resistanceCancer Drug Resistance · 2022
  50. Lysosome-mediated chemoresistance in acute myeloid leukemiaCancer Drug Resistance · 2022